SHOUYAO HOLDINGS (BEIJING) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.83 CNY | -4.72% |
|
-1.69% | -18.77% |
| Sales 2024 * | 10M 1.38M 115M | Sales 2025 * | 46M 6.34M 529M | Capitalization | 6.67B 918M 76.64B |
|---|---|---|---|---|---|
| Net income 2024 * | -173M -23.83M -1.99B | Net income 2025 * | -176M -24.24M -2.02B | EV / Sales 2024 * | 667 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 145 x |
| P/E ratio 2024 * |
-38.3
x | P/E ratio 2025 * |
-38
x | Employees | 185 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 23.55% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.72% | ||
| 1 week | -1.69% | ||
| Current month | +0.52% | ||
| 1 month | -0.60% | ||
| 3 months | -4.84% | ||
| 6 months | -13.29% | ||
| Current year | -18.77% |
1 week
43.30
47.69
1 month
41.0047.77
Current year
26.8155.13
1 year
26.8161.63
3 years
17.5268.00
5 years
17.5268.00
10 years
17.5268.00
| Managers | Title | Age | Since |
|---|---|---|---|
Wen Jun Li
CEO | Chief Executive Officer | 57 | 01/16/01 |
Ya Jie Wang
DFI | Director of Finance/CFO | 54 | 01/17/01 |
Ying Hui Sun
CTO | Chief Tech/Sci/R&D Officer | 44 | 01/10/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xue Liu
BRD | Director/Board Member | 62 | 04/21/04 |
Ting Li
BRD | Director/Board Member | 35 | 01/21/01 |
Wen Jun Li
CEO | Chief Executive Officer | 57 | 01/16/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/24/24 | 44.83 | -4.72% | 295,856 |
| 21/24/21 | 47.05 | +5.40% | 647,892 |
| 20/24/20 | 44.64 | +1.92% | 292,952 |
| 19/24/19 | 43.8 | -1.22% | 124,747 |
| 18/24/18 | 44.34 | -2.76% | 319,760 |
End-of-day quote Shanghai S.E., June 24, 2024
More quotes
Shouyao Holdings Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main business is the research and development of small molecule innovative drugs in the clinical stage. The Company's main products include anaplastic lymphoma kinase (ALK) kinase inhibitors, selective inhibitors and others. The Company's pharmaceutical products are used in key tumor indications such as non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, thyroid cancer, ovarian cancer, and leukemia, as well as disease areas such as type II diabetes. The Company mainly operates in the domestic market.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
44.83
CNY
Average target price
67
CNY
Spread / Average Target
+49.45%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.77% | 918M | |
| +52.70% | 801B | |
| +41.58% | 631B | |
| -4.86% | 359B | |
| +21.96% | 337B | |
| +11.47% | 305B | |
| +17.72% | 245B | |
| +4.46% | 231B | |
| +13.13% | 219B | |
| +10.46% | 171B |
- Stock Market
- Equities
- 688197 Stock
